8-K/A: SUIC Worldwide Holdings Completes Vision Renu Acquisition

SUIC Worldwide Holdings Ltd. has completed the acquisition of a 51% controlling interest in Vision Renu Corporation, a medical device company, through a share exchange agreement.

Summary

• SUIC Worldwide Holdings Ltd. has completed the acquisition of 51% of Vision Renu Corporation for 30,000,000 shares of SUIC Common Stock, representing approximately 35% of SUIC's fully diluted shares.
• The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
• Following the acquisition, there were changes in SUIC's leadership, with Chen King Te appointed as Chairman, Director, and CEO, and Kho Jean Jean as Director and CFO.
• Vision Renu Corporation focuses on R&D and manufacturing of high-tech medical devices, including a Scleral Micro-Ablation Laser System for Presbyopia and a Transcranial Magnetic Stimulation (TMS) Device for depression.
• Vision Renu has secured over 150 unit orders for 2026 and projects over 500 units in 2027 and over 5,000 units in 2028.
• The company is expanding into the Life Science sector, focusing on AI Gene Editing, AI DNA Synthesis, and AI Healthcare.
• Pro forma financial statements indicate a combined net loss attributable to SUIC of $340,970 for the year ended December 31, 2025, and a net loss of $97,460 for the six months ended June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a low score due to significant financial losses and a reverse recapitalization structure, indicating potential underlying financial instability despite strategic acquisitions.

Positives

• Acquisition of Vision Renu Corporation, a company with innovative medical devices in optometry, healthcare, and brain health.
• Vision Renu has a strong product pipeline with a Scleral Micro-Ablation Laser System undergoing FDA certification and a TMS device with existing orders.
• Vision Renu projects significant order growth for its TMS device: over 150 units in 2026, over 500 in 2027, and over 5,000 in 2028.
• Strategic expansion into the Life Science sector with a focus on AI Gene Editing, AI DNA Synthesis, and AI Healthcare.
• The transaction is structured as a tax-free reorganization.
• New leadership appointed with Chen King Te as CEO and Chairman, and Kho Jean Jean as CFO.

Negatives

• The pro forma combined net loss attributable to SUIC was $340,970 for the year ended December 31, 2025.
• The pro forma combined net loss attributable to SUIC was $97,460 for the six months ended June 30, 2026.
• The acquisition was accounted for as a reverse recapitalization, with SUIC being the accounting acquirer, which can sometimes indicate a less robust financial position of the acquirer.
• Significant goodwill of $47,977,876 was recorded on the balance sheet as of December 31, 2025, following the acquisition.
• The company has a substantial accumulated deficit in its historical financial statements.
• The pro forma financial information is preliminary and subject to further revision.

Risks

• The forward-looking statements are subject to risks, uncertainties, and assumptions, including the success of sales, marketing, and product development, competition, and general economic conditions.
• The FDA certification process for the Scleral Micro-Ablation Laser System may not be successful or may take longer than anticipated.
• Market acceptance and adoption of Vision Renu's products, particularly in new markets, could be slower than projected.
• Integration risks associated with combining the operations of SUIC and Vision Renu.
• The company's expansion into AI-driven life sciences is a nascent area with inherent technological and market risks.
• The significant amount of goodwill recorded may be subject to impairment if future performance does not meet expectations.

Future Outlook

Vision Renu projects significant order growth for its TMS device, with over 500 units expected in 2027 and over 5,000 units in 2028. The company is also entering the Life Science sector with a focus on AI Gene Editing, AI DNA Synthesis, and AI Healthcare, anticipating AI to drive significant transitions in the next 20 years.

Management Comments

• The company is entering the Life Science sector and believes that over the next 20 years, AI will drive the life sciences to transition from observing life to designing life.
• Together with our AI instrument, we will focus on AI Gene Editing & AI DNA Synesis, AI Healthcare. The convergence of three core technologies: will give rise to: Precision medicine, Longevity technology, Synthetic biomanufacturing, Digital life engineering.

Industry Context

StockSavvy.ai notes that the acquisition aligns with the growing trend in the medical device industry towards innovative solutions for aging populations and mental health. The focus on AI in life sciences is a forward-looking strategy, positioning the company in a high-growth, albeit speculative, sector.

Comparison to Industry Standards

• The acquisition of a 51% controlling interest via share exchange is a common M&A strategy in the medical device sector.
• Vision Renu's focus on presbyopia and depression treatment aligns with key areas of unmet medical need and growing market demand.
• The projected order growth for the TMS device (500 units in 2027, 5000 in 2028) would need to be benchmarked against established players in the neuromodulation market, such as Magstim or Neuronetics, to assess its competitiveness.
• The company's stated ambition to leverage AI in gene editing and DNA synthesis places it in a highly competitive and rapidly evolving field, with established players like Illumina, Thermo Fisher Scientific, and numerous biotech startups.

Management Changes

Related Party Transactions

• Accounts receivable-related parties and Other receivables-related parties are noted on the balance sheets.
• Other payables-related party are noted on the balance sheets.
• Interest Expense related party loans are noted on the statements of operations.

Stakeholder Impact

• Shareholders: Dilution from the issuance of 30,000,000 new shares; potential future value creation from acquired business and new ventures, but also risk from current losses.
• Employees: The combined entity has 7 full-time employees, with 6 in management and administration, and R&D. Future growth may lead to increased employment.
• Creditors: The company has various liabilities including short-term debt, loan payables, and convertible promissory notes.

Next Steps

• File pro forma and interim reports within 70 days as required by SEC.
• Continue FDA certification process for the Scleral Micro-Ablation Laser System.
• Seek government approval to enter Malaysia, Indonesia, Thailand, and China markets for the TMS device.
• Focus on AI Gene Editing, AI DNA Synthesis, and AI Healthcare initiatives.

Key Dates

Recommendation

The acquisition of Vision Renu brings promising medical device technology and a strategic pivot into AI-driven life sciences. However, the significant pro forma losses, the reverse recapitalization structure, and the substantial goodwill recorded warrant a cautious approach. The company's future success hinges on successful product commercialization, FDA approvals, and effective execution of its AI strategy. A 'hold' recommendation reflects the balance between potential upside and significant risks.

Keywords

medical devices, acquisition, Vision Renu Corporation, Scleral Micro-Ablation Laser System, Transcranial Magnetic Stimulation, AI Gene Editing, AI DNA Synthesis, reverse recapitalization